Acute lung injury (ALI) and its severe manifestation, acute respiratory distress syndrome (ARDS), remain major causes of morbidity and mortality worldwide. Despite significant advances in understanding pulmonary inflammation, epithelial-endothelial barrier dysfunction, immune responses, and tissue repair mechanisms, the translation of preclinical discoveries into effective therapies remains limited. Robust, reproducible, and physiologically relevant experimental methodologies are essential for advancing mechanistic insights and therapeutic development in this field.

A major challenge in ALI research is the complexity and heterogeneity of lung injury caused by diverse insults, including infection, sepsis, trauma, mechanical ventilation, environmental toxins, and ischemia-reperfusion. Variability in experimental models, injury induction strategies, physiological assessments, imaging techniques, molecular analyses, and translational platforms often hinders reproducibility and cross-study comparisons. Furthermore, the rapid emergence of advanced technologies has created a growing need for standardized, validated, and widely accessible methodologies that can accurately capture the multifaceted nature of acute lung injury.

This Collection aims to serve as a comprehensive platform for methodologies that advance the development, characterization, monitoring, and mechanistic investigation of acute lung injury across diverse experimental and translational settings. The collection welcomes both established and innovative approaches that enhance our ability to model disease processes, evaluate pathological responses, investigate cellular and molecular mechanisms, identify therapeutic targets, and assess treatment efficacy.

By consolidating rigorously validated protocols and innovative experimental approaches, this collection will promote reproducibility, facilitate technology adoption, accelerate mechanistic discoveries, and support the development of effective interventions for acute lung injury across basic, translational, and clinical research communities.